Within just three years, Vaxinano has developed versatile mucosal prophylactic or therapeutic vaccines against zoonosis ...

This investment will enable Vaxinano to propel its flagship vaccines and immuno-therapies targeting leishmaniasis, toxoplasmosis, and colibacillosis into clinical trials. Thanks to its Stellar-NP ...

The researchers set out to investigate the effects of multiple mRNA vaccines on mucosal immunity, referring to mucous membranes such as the ones on the inside of our noses. Specifically ...